MedTrace Logo

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

NCT03458260 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2026-03-10

No results posted yet for this study

Summary

This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.

Conditions

  • Aggressive Non-Hodgkin Lymphoma

Interventions

DRUG

Pixantrone

6 cycles - dose = 80mg/m²

OTHER

Ifosfamide

6 cycles - 1500 mg/m2

OTHER

Etoposide

6 cycles - 150 mg/m2

OTHER

Rituximab

6 cycles - 375 mg/m2

PROCEDURE

Transplant

after 2 or 6 cycles

Sponsors & Collaborators

  • The Lymphoma Academic Research Organisation

    lead OTHER

Principal Investigators

  • Luc-Matthieu Fornecker · CHU de Strasbourg

  • Eric Van den Neste · UCL St Luc Bruxelles

  • Sandy Amorin · Hôpital St Louis - Paris

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-26
Primary Completion
2024-12-24
Completion
2024-12-24

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03458260 on ClinicalTrials.gov